APOGEE THERAPEUTICS INC. - COMMON STOCK

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

03 3 2025 06:05:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

03 3 2025 06:00:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

28 2 2025 16:00:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

25 2 2025 07:30:52 提供 Nasdaq GlobeNewswire

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

03 2 2025 07:00:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

29 1 2025 07:30:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

10 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

02 12 2024 06:00:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics Announces Agenda for Virtual R&D Day

29 11 2024 13:00:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

18 11 2024 07:30:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results

12 11 2024 07:00:01 提供 Nasdaq GlobeNewswire

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

04 11 2024 07:30:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

24 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

16 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

12 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

09 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

19 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

12 8 2024 06:30:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

28 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

23 5 2024 07:30:00 提供 Nasdaq GlobeNewswire